Mastering Heart Failure with Preserved Ejection Fraction (HFpEF) Guidelines for SCE Cardiology Success

Introduction

Heart Failure with Preserved Ejection Fraction (HFpEF) represents one of the most challenging diagnoses in modern cardiology, accounting for approximately 50% of all heart failure cases. For SCE Cardiology candidates, mastering the diagnostic criteria, classification, and management guidelines for HFpEF is essential for exam success and clinical practice.

Understanding HFpEF: Pathophysiology and Clinical Significance

HFpEF is characterized by typical symptoms and signs of heart failure with a left ventricular ejection fraction (LVEF) that is preserved (typically ≥50%). Unlike heart failure with reduced ejection fraction (HFrEF), HFpEF exhibits distinct pathophysiological features including:

• Diastolic dysfunction: Impaired relaxation of the left ventricle

• Ventricular stiffening: Reduced compliance of the myocardial tissue

• Systemic microvascular dysfunction: Endothelial dysfunction contributing to elevated filling pressures

• Comorbidities-driven pathophysiology: Conditions like hypertension, diabetes, obesity, and ageing contribute significantly to HFpEF development

Diagnostic Criteria: The H₂FPEF and ESC Criteria

ESC 2021/2023 Guidelines Criteria

The ESC Heart Failure Association criteria require the presence of:

1. Symptoms and signs of heart failure

2. LVEF ≥ 50% (or 41-49% for "mid-range" HFpEF - HFmrEF)

3. Evidence of structural heart disease (LVH, LA enlargement) OR diastolic dysfunction

4. Elevated natriuretic peptides (BNP > 35 pg/mL or NT-proBNP > 125 pg/mL)

5. Additional objective evidence of cardiac dysfunction

H₂FPEF Score

The H₂FPEF score is a validated clinical tool for diagnosing HFpEF in patients with unexplained dyspnea:

Score interpretation:

• 0-1: HFpEF unlikely

• 2-5: Intermediate probability

• ≥6: HFpEF likely

Classification and Staging

ESC Classification (2021)

• HFpEF: LVEF ≥ 50%

• HFmrEF (Heart Failure with mildly reduced Ejection Fraction): LVEF 41-49%

• HFrEF: LVEF ≤ 40%

ACC/AHA Stages

• Stage A: At risk (hypertension, diabetes, obesity)

• Stage B: Pre-HF (structural changes, no symptoms)

• Stage C: Symptomatic HF

• Stage D: Advanced HF

Management Guidelines: SCE High-Yield Points

Key Recommendations from ESC 2021/2023 and NICE Guidelines

1. Treat Underlying Comorbidities (First Line)

This is the cornerstone of HFpEF management:

• Hypertension: Target BP < 130/80 mmHg (ACC/AHA). Use ACE inhibitors, ARBs, or ARNIs

• Atrial fibrillation: Rate/rhythm control according to CHA₂DS₂-VASc score

• Diabetes: Consider SGLT2 inhibitors (empagliflozin, dapagliflozin)

• Obesity: Weight management programs

• Coronary disease: Revascularization where indicated

2. Diuretics

• Loop diuretics (furosemide, bumetanide) for volume overload

• Start low, titrate according to symptoms and weight

• Monitor electrolytes and renal function

3. Specific Pharmacotherapy

SGLT2 Inhibitors (Game Changer!)

Recent trials have revolutionized HFpEF management:

• Empagliflozin: EMPEROR-Preserved trial showed 21% reduction in CV death or HF hospitalization

• Dapagliflozin: DELIVER trial demonstrated 18% reduction in worsening HF events

SCE Key Point: SGLT2 inhibitors are now recommended for HFpEF regardless of diabetes status (Class I, Level A evidence)

ARNIs (Sacubitril/Valsartan)

• PARAGON-HF trial showed benefit in certain HFpEF subgroups

• Consider in patients with LVEF in the lower range (41-49%)

Mineralocorticoid Receptor Antagonists (MRAs)

• TOPCAT trial showed modest benefit, especially in patients with elevated BNP

• Consider eplerenone or spironolactone

• Monitor potassium and renal function

Non-Pharmacological Management

• Sodium restriction: < 2g/day

• Fluid restriction: 1.5-2L/day in advanced cases

• Exercise rehabilitation: Cardiac rehab programs

• Weight monitoring: Daily weights

• Vaccination: Influenza and pneumococcal

HFmrEF (Mid-Range Ejection Fraction)

A important distinction for SCE exams:

• LVEF 41-49%

• May benefit from similar therapies as HFrEF (ARNIs, MRAs, beta-blockers)

• ESC guidelines give IIb recommendations for these agents

Exam-Focused Summary: Key Points to Remember

1. Diagnosis requires: Symptoms + LVEF ≥50% + elevated natriuretic peptides + evidence of diastolic dysfunction

2. H₂FPEF score >6 makes HFpEF likely

3. First-line treatment: Aggressive management of comorbidities

4. SGLT2 inhibitors are now first-line (Class I, Level A)

5. Diuretics for symptom relief in volume overload

6. Prognosis: Similar to HFrEF; high morbidity and mortality

Conclusion

HFpEF management has evolved dramatically with the advent of SGLT2 inhibitors. For SCE Cardiology success, remember that treating comorbidities is foundational, and SGLT2 inhibitors have transformed our therapeutic approach. Understand the diagnostic criteria, scoring systems, and current guideline recommendations to excel in your examination.

Focus on the ESC 2023 focused update and NICE guidelines for the most current recommendations. Practice applying the H₂FPEF score to clinical scenarios, as this is frequently tested in SCE examinations.